ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply

Affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK; National Institute of Health Research, Oxford Biomedical Research Centre, Oxford, UK.
² Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK; National Institute of Health Research, Oxford Biomedical Research Centre, Oxford, UK. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.

Comment

Merryn Voysey et al. Lancet. 2020.

. 2020 Nov 7;396(10261):1486-1487.

doi: 10.1016/S0140-6736(20)32267-4.

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK; National Institute of Health Research, Oxford Biomedical Research Centre, Oxford, UK.
² Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK; National Institute of Health Research, Oxford Biomedical Research Centre, Oxford, UK. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.

No abstract available

Comment on

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Folegatti PM, et al. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702298 Free PMC article. Clinical Trial.

1. Folegatti PM, Ewer KJ, Aley PK. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. - PMC - PubMed